SDS acute toxicity testing provides the essential hazard data required to complete Section 11 (Toxicological Information) of a Safety Data Sheet and to assign accurate GHS classification and labeling for chemicals entering global markets. This guide explains the principal test routes (oral, dermal, and inhalation), internationally recognized OECD test methods, applicable regulatory frameworks, and practical considerations for manufacturers seeking compliant SDS documentation.
Technical Overview
Acute toxicity refers to the adverse effects that occur following a single or short-term exposure to a substance, typically within 24 hours, via the oral, dermal, or inhalation route. Under the UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS), acute toxicity is one of the core health hazard endpoints that directly determines the hazard pictograms, signal words, and hazard statements appearing on product labels and in Section 2 and Section 11 of the Safety Data Sheet (SDS).
SDS acute toxicity testing is performed to generate or verify the data needed to classify a substance or mixture into GHS acute toxicity Categories 1 through 5. Classification is based on the Acute Toxicity Estimate (ATE), expressed as LD50 (median lethal dose, mg/kg body weight) for oral and dermal routes, or LC50 (median lethal concentration, in ppm, mg/L, or mg/m³) for inhalation. The resulting classification drives downstream obligations including labeling, packaging, worker protection measures, and transport dangerous goods classification.
Because whole-animal testing is increasingly restricted, modern testing strategies follow the principle of the 3Rs (Replacement, Reduction, Refinement). Data generation increasingly relies on a weight-of-evidence approach that combines existing data, read-across from structurally analogous substances, in vitro methods, quantitative structure-activity relationship (QSAR) models, and, only where necessary, confirmatory in vivo studies conducted under internationally accepted test guidelines such as those published by the OECD.
Testing Samples
Industrial Chemicals and Intermediates
Raw materials, solvents, monomers, catalysts, and synthetic intermediates used in manufacturing processes frequently require acute toxicity data for SDS authoring, especially when placing new substances on the market under regulations such as EU REACH, UK REACH, or K-REACH. Both neat substances and technical-grade mixtures containing relevant impurities can be evaluated.
Consumer and Household Products
Cleaning agents, detergents, air fresheners, paints, adhesives, and automotive care products intended for consumer or professional use must be classified for acute toxicity. For mixtures, testing or calculation-based approaches using ingredient ATE values are applied to derive the mixture classification reported in the SDS.
Agrochemicals and Pesticides
Active ingredients and formulated plant protection products require comprehensive acute toxicity profiles covering all three exposure routes. Regulatory frameworks such as the FAO/WHO Joint Meeting on Pesticide Specifications (JMPS), the US EPA FIFRA, and Regulation (EC) No 1107/2009 mandate acute oral, dermal, and inhalation toxicity data, along with irritation and sensitization endpoints, for product registration and SDS preparation.
Pharmaceutical and Biocidal Substances
Active pharmaceutical ingredients (APIs), excipients, intermediates, and biocidal active substances require acute toxicity characterization for occupational SDSs covering manufacturing and handling operations, even when clinical data exist for therapeutic use, because exposure scenarios and dose levels differ substantially.
Battery, Electronics, and Specialty Materials
Electrolytes, electrode materials, nanomaterials, and other specialty substances increasingly require SDS documentation for supply chain compliance, often with acute toxicity assessment supported by non-animal methods where physicochemical properties permit.
Testing Items
The core acute toxicity endpoints for SDS purposes are organized by exposure route and supplemented by closely related local tissue effects that appear alongside acute systemic toxicity in Section 11 of the SDS:
- Acute oral toxicity: determination of LD50 or a derived ATE value following single-dose oral administration, classifying the substance into GHS Categories 1–5.
- Acute dermal toxicity: determination of LD50 following a single 24-hour dermal application to intact skin under occlusive conditions.
- Acute inhalation toxicity: determination of LC50 following a defined exposure period (typically 4 hours) to gases, vapors, or dusts, mists, and aerosols, with route-specific cut-off values for each physical form.
- Skin corrosion and irritation: supporting classification for GHS skin categories and selection of appropriate first-aid and personal protection measures in the SDS.
- Serious eye damage and eye irritation: supporting classification for Category 1 (irreversible effects) or Category 2 (reversible irritation).
- Skin sensitization and respiratory sensitization hazard identification, which together with acute toxicity determines key precautionary statements.
- Mixture classification calculations: derivation of mixture ATE values from ingredient toxicity data, including handling of ingredients with unknown toxicity under the additivity formula.
Testing Methods
Testing is conducted in accordance with OECD Guidelines for the Testing of Chemicals, which are formally recognized by major regulatory authorities worldwide, including those of the United States, the European Union, China, Japan, and Korea. Test facilities should operate under Good Laboratory Practice (GLP) where results are submitted to regulatory agencies.
Acute Oral Toxicity Methods
- OECD TG 420 (Acute Toxic Class Method): a stepwise dosing procedure using fixed dose levels (typically 300 and 2000 mg/kg) that reduces animal use while allowing category classification without precise LD50 calculation.
- OECD TG 423 (Fixed Dose Procedure): sequential administration of fixed doses with observation of evident toxicity, enabling classification based on survival and clinical signs at defined dose steps.
- OECD TG 425 (Up-and-Down Procedure): a sequential method that tests animals one at a time, dose levels adjusted based on outcomes; where lethality is not observed up to the limit dose of 2000 or 5000 mg/kg, the substance may be classified as Category 5 or unclassified.
Acute Dermal Toxicity Method
- OECD TG 402 (Acute Dermal Toxicity): single 24-hour dermal application at graduated dose levels to determine the dermal LD50, typically in rats or rabbits, with limit testing at 2000 mg/kg where justified.
Acute Inhalation Toxicity Methods
- OECD TG 403 (Acute Inhalation Toxicity): nose-only or whole-body exposure for 4 hours to determine the LC50 with concentration-response characterization.
- OECD TG 436 (Acute Toxic Class Method for Inhalation): a limit-concentration approach that allows classification without a full LC50 determination when no mortality occurs at the regulatory limit concentration.
Alternative and Non-Animal Approaches
- Read-across and category approaches: extrapolation of acute toxicity data from structurally or toxicologically similar analogues, documented in a robust study summary for regulatory acceptance.
- QSAR modeling: computational prediction of acute toxicity using validated tools where the substance falls within the applicability domain of the model.
- In vitro and ex vitro methods: validated alternatives such as reconstructed human epidermis models and bovine cornea assays supporting local irritation endpoints, with in chemico and in vitro strategies for sensitization assessment under OECD TG 442C/442D/442E.
- Weight-of-evidence evaluation: integration of human epidemiological data, occupational exposure experience, and existing animal studies to avoid redundant testing, consistent with REACH Annex XI and GHS provisions.
Applications
SDS acute toxicity testing results are applied across the entire chemical product compliance lifecycle:
- GHS, CLP, and national classification: assignment of hazard classes, signal words (Danger or Warning), and hazard statements such as H300, H301, H302, H310, H311, H312, H330, H331, and H332 for labels and SDS Sections 2, 9, and 11.
- Transport of dangerous goods: classification under the UN Model Regulations, ADR, IMDG Code, and IATA DGR for Class 6.1 (toxic substances) and related packing group assignment.
- REACH and global registration: fulfillment of Annex VII information requirements for substances manufactured or imported above one tonne per year within the EU and corresponding obligations under K-REACH, Turkey KKDIK, and similar frameworks.
- Occupational health and safety: definition of occupational exposure controls, engineering measures, and personal protective equipment specifications in SDS Section 8, aligned with OSHA HazCom 2012 and China GB/T 16483 requirements.
- Emergency response: first-aid measures in SDS Section 4 and poison center notifications, where acute toxicity data inform medical management of accidental ingestion, skin contact, or inhalation.
- Product stewardship and customer documentation: support for downstream user SDSs, corporate hazard communication programs, and supply chain questionnaire responses.
FAQ
Is animal testing always required for SDS acute toxicity classification?
No. Regulatory authorities strongly encourage the use of existing data, read-across, QSAR predictions, and in vitro methods before conducting new in vivo studies. For many well-characterized substances and mixtures, classification can be completed entirely from existing information, and mixture classifications can often be calculated using the additivity formula with ingredient ATE values.
How long does an acute toxicity test take?
In vivo acute toxicity studies, including a 14-day post-exposure observation period, typically require three to six weeks from test initiation to final report. Non-animal approaches such as QSAR assessment or read-across documentation can often be completed within one to two weeks.
What sample quantity is needed for testing?
Required quantities vary by route and method: oral and dermal limit tests generally require 10 to 50 grams of test substance, while inhalation studies may require substantially larger volumes depending on exposure concentration, chamber type, and test duration. The testing laboratory confirms exact requirements during study design.
How are GHS acute toxicity categories assigned?
Categories are assigned based on ATE cut-off values that differ by exposure route. For the oral route, Category 1 applies at or below 5 mg/kg, Category 2 above 5 to 50 mg/kg, Category 3 above 50 to 300 mg/kg, Category 4 above 300 to 2000 mg/kg, and Category 5 above 2000 to 5000 mg/kg. Dermal and inhalation routes have their own route-specific and physical-form-specific cut-off values.
Do mixtures need separate acute toxicity testing?
Usually not. Under GHS, mixture classification is preferentially performed by calculation using ingredient ATE values, with tiered provisions for applying existing mixture test data, bridging principles for similar formulations, and cut-off concentration rules for ingredients with unknown toxicity. Direct mixture testing is generally a last resort.
Which standards govern SDS format and acute toxicity reporting?
The SDS format follows the GHS-aligned 16-section structure, implemented regionally through regulations such as Regulation (EC) No 1907/2006 (REACH) Annex II in the EU, OSHA Hazard Communication Standard 29 CFR 1910.1200 in the United States, and GB/T 16483 and GB/T 17519 in China. Testing itself follows OECD Test Guidelines, with GLP compliance required for regulatory submissions.
How often should acute toxicity data in an SDS be reviewed?
SDS content should be reviewed and updated whenever new hazard information becomes available, when classification criteria change, or at defined intervals required by applicable regulations, typically every three to five years depending on jurisdiction. Any confirmed change in acute toxicity classification triggers label and SDS revision obligations.